Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efficient designs for testing new agents and regimens

A Ardizzoni1

  • 1Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Chest
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

ESMO open·2025
Same author

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).

ESMO open·2024
Same author

Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: a case series.

Acta gastro-enterologica Belgica·2021
Same author

Skip pattern approach toward the early access of innovative anticancer drugs.

ESMO open·2021
Same author

Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy.

Journal of cancer policy·2021
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026
See all related articles

This study proposes novel clinical trial designs for non-small cell lung cancer (NSCLC) chemotherapy, aiming for faster, more efficient drug evaluation with fewer patients. These methods could accelerate the identification of effective treatments for lung cancer.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacology

Background:

  • Current non-small cell lung cancer (NSCLC) chemotherapy trials are lengthy, costly, and yield disappointing results.
  • Existing alternative trial designs offer benefits like reduced patient numbers and shorter durations.

Purpose of the Study:

  • To propose an improved clinical trial methodology for NSCLC chemotherapy.
  • To enhance the efficiency and speed of identifying effective cancer therapies.

Main Methods:

  • Combining phase II screening, randomized phase II studies, and multicenter, comparative, randomized phase III trials.
  • Discussing the integration of diverse disease stages within phase II studies.
  • Addressing patient recruitment challenges for large-scale trials.

Related Experiment Videos

Main Results:

  • The proposed integrated approach facilitates earlier identification of ineffective or highly active agents and regimens.
  • This methodology allows for smaller patient cohorts and shorter trial durations compared to traditional designs.

Conclusions:

  • The proposed alternative clinical trial design offers a more efficient pathway for NSCLC chemotherapy research.
  • This strategy can accelerate the development of novel and effective lung cancer treatments.